VistaGen Therapeutics Q1 2026 Earnings Report

VistaGen Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.46
• Beat/Miss: N/A
• One Year Ago EPS: N/A

VistaGen Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.22 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

VistaGen Therapeutics Announcement Details

• Quarter: Q1 2026
• Date: 8/7/2025
• Time: After Market Closes
• Conference Call Date: Thursday, August 7, 2025
• Conference Call Time: 5:00PM ET

VistaGen Therapeutics (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.